Vii

Geron Corporation Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Geron Corporation, U.S. Securities and Exchange Commission, MF, Private Securities Litigation Reform Act, Xi, GAAP, Telephone, Nasdaq, Imetelstat, Pharmacokinetics, Company, Safety, Research, Microdeletion syndrome, RBC, Corporation, Patient, Security (finance), Depreciation, Review, ESA, Webcast, Clinical trial, FDA, Apoptosis, TI, Fast Track, Income, Vii, Achievement, Disease, Lymphatic system, MDS, Intellectual property, ID, JAK, Risk, Exercise, Pharmaceutical industry, Video game

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.
  • Total operating expenses for the first quarter of 2022 were $28.8 million compared to $28.6 million for the same period in 2021.
  • ET on Monday, May 9, 2022 to review recent events and first quarter 2022 financial results.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.

CDK Global, Inc. Announces Early Results of Its Tender Offer and Consent Solicitation for Its 2024 Notes

Retrieved on: 
Monday, May 9, 2022
Communication, Mini-tender offer, Failure, CDK, Agreement, Adoption, Sub, Vii, SEC, Credit Suisse, Solution, Plan, Risk, Forward-looking statement, NASDAQ, Control, Company, Uncertainty, Software as a service, Nature, Settlement date, Purchase price allocation, Time, CDK Global, Constitutional amendment, Convention to propose amendments to the United States Constitution, Sale, Accrued interest, Ownership, LLC, Consent, Annual report, Software, Expiration, Expiration date, Personal Information Agent, Form 10-K, Tender offer, The Purchase Price, Life insurance, Security (finance), Bank, Risk management, Note, Indenture, Acquisition, Solicitation, Purchasing

Pursuant to the terms of the 2024 Notes, the interest rate adjusts from time to time and is currently 5.000%.

Key Points: 
  • Pursuant to the terms of the 2024 Notes, the interest rate adjusts from time to time and is currently 5.000%.
  • The Tender Offer will only be made pursuant to the terms of the Offer to Purchase and Consent Solicitation Statement.
  • Holders may obtain copies of the Offer to Purchase and Consent Solicitation Statement from the Information Agent and Tender Agent for the Tender Offer, D.F.
  • Credit Suisse Securities (USA) LLC is the Dealer Manager for the Tender Offer and Solicitation Agent for the Solicitation.

AST SpaceMobile Announces $75 Million Committed Equity Facility

Retrieved on: 
Friday, May 6, 2022
Technology, Satellite, Mobile, Wireless, Telecommunications, Networks, Internet, U.S. Securities and Exchange Commission, Communication, YouTube, Twitter, NASDAQ, Gaps, LLC, Bluebird, Public expenditure, Common stock, AST, Security (finance), Partnership, Risk, Marketing, LinkedIn, Intention, Sale, Vii, EDGAR, IP, SEC, Terminology, Research, Acquisition, Mobile phone, Risk management, Facebook

The agreement governs a Committed Equity Facility that provides AST SpaceMobile with the right, without obligation, to sell and issue up to $75 million of its Class A Common Stock over a period of 24 months to B. Riley at AST SpaceMobiles sole discretion, subject to certain limitations and conditions.

Key Points: 
  • The agreement governs a Committed Equity Facility that provides AST SpaceMobile with the right, without obligation, to sell and issue up to $75 million of its Class A Common Stock over a period of 24 months to B. Riley at AST SpaceMobiles sole discretion, subject to certain limitations and conditions.
  • The facility allows us the flexibility to raise equity capital, when and if we choose to do so, at a measured pace, depending on market conditions.
  • For more information, follow AST SpaceMobile on Facebook, Twitter, LinkedIn and YouTube.
  • AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

Dalata Hotel Group PLC: Holding(s) in Company

Retrieved on: 
Friday, May 6, 2022
Council Implementing Regulation (EU) No. 282/2011, Central Bank of the Republic of Turkey, Disclosure, Acquisition, Person, Ix, Letter, EC, Intention, Vii, Central bank, LEI, Life, Exercise, Security (finance), Auction, Medical device, EU, Regulation, Transparency

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    i.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).

Astra Announces First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
Aerospace, Manufacturing, Satellite, Other Technology, Technology, COVID-19, NASA, Weather, FAA, Cyprus Securities and Exchange Commission, Forward-looking statement, Investment, Mission statement, GAAP, EBITDA, Failure, NASDAQ, ASTR, Public expenditure, Annual report, United Launch Alliance, ULA, Security (finance), Depreciation, Webcast, Industry, Capital, Investor relations, Form 10-K, History, Forecasting, Income, Cape Canaveral, Vii, Capital expenditure, SEC, Life, CEO, Growth, COVID-19 testing, Acquisition, Video game, Communications satellite, Renewable energy, Online gambling, Bank, Bookkeeping, Weapon, Risk management, Adjustment, Nasdaq, Ridesharing

Astra Space, Inc. (Astra) (Nasdaq: ASTR) today announced financial results for its first quarter ended March 31, 2022.

Key Points: 
  • Astra Space, Inc. (Astra) (Nasdaq: ASTR) today announced financial results for its first quarter ended March 31, 2022.
  • First Quarter 2022 Financial Highlights:
    For the three months ended March 31, 2022:
    GAAP Net Loss was $(85.7) million.
  • As of May 5, 2022, we are providing guidance for the second quarter 2022 based on current market conditions and expectations.
  • ET) today to discuss first quarter results and our outlook for the second quarter ending June 30, 2022.

RCI 2Q22 Call on Twitter Spaces on Monday, May 9th; First to Use Twitter's Audio Platform for an Earnings Call

Retrieved on: 
Thursday, May 5, 2022
Bitcoin, COVID-19, Twitter, Nasdaq, U.S. Securities and Exchange Commission, Q&A, NFT, Annual report, Sport, RCI Hospitality Holdings, Form 10-K, Adult, Cabaret, Wall Street, Vii, Tootsie, CEO, News, Technology, XTC, City, RCI, Social media, Multimedia, Public relations

After the market closes and before the call, RCI plans to issue its earnings news release and file its 10-Q for the quarter ended March 31st.

Key Points: 
  • After the market closes and before the call, RCI plans to issue its earnings news release and file its 10-Q for the quarter ended March 31st.
  • After the call, investors can meet management at 8 PM ET at Tootsie's Cabaret, RCI's 74,000 square foot mega club in Miami.
  • Eric Langan, President and CEO of RCI Hospitality Holdings, Inc., said, "Twitter Spaces is part of our strategy of harnessing new technology to expand our reach and attract new customers and investors.
  • The company has no obligation to update or revise the forward-looking statements to reflect the occurrence of future events or circumstances.

SIGA Reports Financial Results for Three Months Ended March 31, 2022

Retrieved on: 
Thursday, May 5, 2022
Xi, Development, Infection, Contract, Human, Annual report, Monkeypox, SIGA Technologies, Vii, Risk, Smallpox, Forward-looking statement, Immune system, European Medicines Agency, Director, Company, Immunotherapy, Neoplasm, FDA, Ix, Meridian Medical Technologies Inc., Executive order, Government, Health Canada, Research, Public Health Agency of Canada, Vaccinia, Income, Private Securities Litigation Reform Act, EMA, Policy, Genome, Time, CMOS, MAA, Vaccine, IV, PHAC, Protein, Documentation, Exercise, Board, BARDA, COVID-19, Food, Cancer, Patent, Investor relations, Phrase, Conference, Vaccination, Public Health Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Cowpox, Construction, Pharmaceutical industry, Meridian, EU

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2022.

Key Points: 
  • The special dividend is payable on June 2, 2022 to shareholders of record at the close of business on May 17, 2022.
  • In January 2022, the European Medicines Agency(EMA) approved the marketing authorisation application (MAA) for oral Tecovirimat SIGA, the same formulation that was approved by theU.S.
  • In January 2022, SIGA announced a research collaboration with Bioarchitech, aUnited Kingdom-based biotech company developing immunotherapy for the treatment of cancer.
  • During the first quarter of 2022, SIGA repurchased approximately 1.0 million shares of its common stock, for approximately $6.6 million.

Maravai LifeSciences Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Earnings per share, Cyprus Securities and Exchange Commission, Income, Investment, Forward-looking statement, GAAP, EBITDA, LLC, Accounting, Tax, Biotechnology, ASC, Safety, Security (finance), Depreciation, Ix, Annual report, Adoption, Class, Private Securities Litigation Reform Act, Vaccine, Sale, Vii, Melamaravakkadu, EPS, Research, Insurance, Bank, Pharmaceutical industry, Fine chemical

(9) Represents income tax benefits at Maravai LifeSciences Holdings, Inc. related to the income tax treatment of income derived from sales to foreign-domiciled customers.

Key Points: 
  • (9) Represents income tax benefits at Maravai LifeSciences Holdings, Inc. related to the income tax treatment of income derived from sales to foreign-domiciled customers.
  • The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.
  • ET to discuss its financial results for the first quarter of fiscal year 2022.
  • Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.

SIGA Declares Special Dividend of $0.45 Per Share

Retrieved on: 
Thursday, May 5, 2022
Board, BARDA, COVID-19, Optimism, Smallpox, Contract, Forward-looking statement, Private Securities Litigation Reform Act, Xi, EMA, NASDAQ, GLOBE, Development, Director, Company, Policy, Risk, FDA, Ix, Human, Annual report, Patent, SIGA Technologies, Government, Phrase, Vaccine, Vii, IV, Health Canada, Vaccination, Infection, CEO, Research, Documentation, Exercise, Pharmaceutical industry

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.

Key Points: 
  • NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.
  • The special dividend is payable on June 2, 2022 to shareholders of record at the close of business on May 17, 2022.
  • Phil Gomez, CEO of SIGA, commented, Based on the Companys current cash resources and its strong balance sheet, we believe it is an appropriate time to declare a special dividend.
  • The special dividend declaration reflects confidence from the financial performance of SIGA in 2020 and 2021, as well as optimism about the Companys business prospects going forward.

MaxLinear to Acquire Silicon Motion

Retrieved on: 
Thursday, May 5, 2022
Technology, Hardware, Semiconductor, Communication, 100,000, Failure, Public expenditure, Wilson Sonsini Goodrich & Rosati, Register, Vii, Motion, Securities Exchange Act of 1934, Goldman Sachs, Solution, CEO, SEC, Technology, Risk, Central Bank of Denver, N.A. v. First Interstate Bank of Denver, N.A., NASDAQ, Securities Act of 1933, IR, Prospectus, Industry, Epidemic, Wells Fargo, Pandemic, L.L.C, ADS, Personal computer, Solid-state drive, THE, Silicon, U.S. Securities and Exchange Commission, Security (finance), Terrorism, MXL, P.C, Sale, Growth, Multimedia, XV, Acquisition, COVID-19, Calendar, Original equipment manufacturer, Form, K&L Gates, Public sector, SSD, Proxy, Conference, Terminology, Video game, Cryptocurrency, American, Silicon Motion, MaxLinear

In the merger, each American Depositary Share (ADS) of Silicon Motion, which represents four ordinary shares of Silicon Motion, will receive $93.54 in cash and 0.388 shares of MaxLinear common stock, for total per ADS consideration of $114.34 (based on MaxLinears May 4, 2022 closing price).

Key Points: 
  • In the merger, each American Depositary Share (ADS) of Silicon Motion, which represents four ordinary shares of Silicon Motion, will receive $93.54 in cash and 0.388 shares of MaxLinear common stock, for total per ADS consideration of $114.34 (based on MaxLinears May 4, 2022 closing price).
  • Together, MaxLinear and Silicon Motion will have expanded resources to better support the combined companys broad customer relationships with their long-term storage requirements.
  • For 20 years, we have built Silicon Motion with a commitment to advancing innovation, partnering with all of our valued customers and supporting our colleagues around the world, said Wallace Kou, President and Chief Executive Officer of Silicon Motion.
  • Under the terms of the definitive agreement, the transaction consideration will consist of $93.54 in cash and 0.388 shares of MaxLinear stock for each Silicon Motion ADS (American Depositary Share) and $23.385 in cash and 0.097 shares of MaxLinear common stock for each Silicon Motion ordinary share not represented by an ADS.